Purinostat mesylate injections versus oral selinexor for relapsed or refractory diffuse large B‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with relapsed or refractory diffuse large B‑cell lymphoma who have received at least two prior systemic therapies are enrolled and assigned to receive one of two treatments. The experimental arm receives purinostat mesylate intravenously (11.2 mg/m2 on days 1, 4, 8 and 11 of a 21‑day cycle) for up to six cycles, while the control arm receives oral selinexor 60 mg twice weekly in 4‑week cycles. The main outcomes are objective response rate and overall survival as determined by a blinded independent central review (BICR). Safety and tolerability are monitored throughout treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years, no gender restrictions;
2. Histologically-confirmed DLBCL, Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy (2-5 lines);
3. Participants must have measurable disease;
4. ECOG≤2;
5. Adequate organ function

Exclusion Criteria:

1. Pregnancy or breastfeeding;
2. Previous history of transplantation;
3. Double/Triple Hit B cell lymphoma;
4. Patient with known active infection, or reactivation of a latent infection;
5. Any serious diseases that investigator deems inappropriate to participate.

Where it's running

• West China Hospital Sichuan University
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Liangkun Sun
• Email: liangkunsun@zenitar.cn
• Phone: 86+15885742617

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Natalizumab to help prevent brain-related side effects during CAR-T therapy in certain lymphoma patients

  This phase 2 study tests whether natalizumab can reduce severe ICANS in adults with recurrent or refractory DLBCL or MCL receiving CAR-T therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07892027

• Lymphodepletion with low-dose whole-body radiation before standard CAR-T therapy for large B-cell lymphoma

  This early-phase trial tests if adding low-dose total body irradiation before standard lymphodepletion and tisagenlecleucel CAR-T therapy is safe and helps patients with relapsed or refractory large B-cell lymphoma see better responses.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07676877

• Fecal transplant to restore gut microbiome before CAR T therapy for relapsed or refractory B‑cell lymphoma

  This trial will test whether a fecal microbiome transplant can restore healthy gut bacteria and improve outcomes for adults with relapsed or refractory CD19 B‑cell lymphoma who received high‑risk antibiotics and are receiving CAR T‑cell therapy.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07042438

• Epcoritamab with platinum chemotherapy and autologous stem cell transplant for relapsed or refractory large B-cell lymphoma

  This trial tests whether adding epcoritamab to standard platinum-based salvage chemotherapy followed by an autologous stem cell transplant helps adults with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06905509

• Zanubrutinib plus sonrotoclax for relapsed or refractory B‑cell non‑Hodgkin lymphoma in underrepresented racial and ethnic groups

  This phase 1 trial tests whether combining zanubrutinib and sonrotoclax can help adults from underrepresented racial and ethnic groups whose B‑cell non‑Hodgkin lymphoma has returned or not responded to prior treatment.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06859008

• Odronextamab with CAR T‑cell therapy for relapsed or refractory diffuse large B‑cell lymphoma

  This trial tests whether giving odronextamab before or after CAR T‑cell therapy helps adults with diffuse large B‑cell lymphoma that has relapsed or not responded to prior treatments.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06854159

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.